Prognostic stratification of colorectal cancer patients: Current perspectives

Cancer Management and Research

Volumn 6, Issue 1, 2014, Pages 291-300

  Schneider, Nora I ^a   Langner, Cord ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Blood vessel invasion; Colorectal cancer; Lymphatic invasion; Perineural invasion; Tumor budding; Tumor necrosis

Indexed keywords

ADENOCARCINOMA; BLOOD VESSEL INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; COLLOID CARCINOMA; COLORECTAL CANCER; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INFLAMMATION; LYMPH VESSEL METASTASIS; MEDULLARY CARCINOMA; MICROPAPILLARY ADENOCARCINOMA; NEOPLASM; PERINEURAL INVASION; REVIEW; SIGNET RING CARCINOMA; TUMOR BUDDING; TUMOR INVASION; TUMOR NECROSIS;

EID: 84903944646     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S38827     Document Type: Review

References (101)

1. Compton CC. Optimal pathologic staging: defining stage II disease. Clin Cancer Res. 2007; 13(22 Pt 2): 6862s-6870s.
2. McLeod HL, Murray GI. Tumour markers of prognosis in colorectal cancer. Br J Cancer. 1999; 79(2): 191-203.
3. Lyall MS, Dundas SR, Curran S, Murray GI. Profiling markers of prognosis in colorectal cancer. Clin Cancer Res. 2006; 12(4): 1184-1191.
4. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004; 96(19): 1420-1425.
5. Hamilton SR, Bosman FT, Boffetta P, etal. Carcinoma of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: IARC; 2010: 134-146.
6. Du W, Mah JT, Lee J, Sankila R, Sankaranarayanan R, Chia KS. Incidence and survival of mucinous adenocarcinoma of the colorectum: a population-based study from an Asian country. Dis Colon Rectum. 2004; 47(1); 78-85.
7. Stewart SL, Wike JM, Kato I, Lewis DR, Michaud F. A population-based study of colorectal cancer histology in the United States, 1998-2001. Cancer. 2006; 107(Suppl 5): 1128-1141.
8. Xie L, Villeneuve PJ, Shaw A. Survival of patients diagnosed with either colorectal mucinous or non-mucinous adenocarcinoma: a population-based study in Canada. Int J Oncol. 2009; 34(4); 1109-1115.
9. Chew MH, Yeo SA, Ng ZP, etal. Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2, 764 sporadic colorectal cancers. Int J Colorect Dis. 2010; 25(10); 1221-1229.
10. Langner C, Harbaum L, Pollheimer MJ, etal. Mucinous differentiation in colorectal cancer-indicator of poor prognosis? Histopathology. 2012; 60(7): 1060-1072.
11. Mekenkamp LJ, Heesterbeek KJ, Koopman M, etal. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer. 2012; 48(4): 501-509.
12. Hyngstrom JR, Hu CY, Xing Y, etal. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol. 2012; 19(9): 2814-2821.
13. Gao P, Song YX, Xu YY, etal. Does the prognosis of colorectal mucinous carcinoma depend upon the primary tumour site? Results from two independent databases. Histopathology. 2013; 63(5): 603-615.
14. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer. 2000; 88(7); 1739-1757.
15. Verhulst J, Ferdinande L, Demetter P, Ceelen W. Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis. J Clin Pathol. 2012; 65(5): 381-388.
16. Minoo P, Zlobec I, Peterson M, Terracciano L, Lugli A. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol. 2010; 37(3): 707-718.
17. Kang H, O'Connell JB, Maggard MA, Sack J, Ko CY. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum. 2005; 48(6): 1161-1168.
18. Nitsche U, Zimmermann A, Späth C, etal. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann Surg. 2013; 258(5): 775-782; discussion 782-783.
19. Thota R, Fang X, Subbiah S. Clinicopathological features and survival outcomes of primary signet ring cell and mucinous adenocarcinoma of colon: retrospective analysis of VACCR database. J Gastrointest Oncol. 2014; 5(1): 18-24.
20. Sung CO, Seo JW, Kim KM, Do IG, Kim SW, Park CK. Clinical significance of signet-ring cells in colorectal mucinous adenocarcinoma. Mod Pathol. 2008; 21(12): 1533-1541.
21. Pande R, Sunga A, Levea C, etal. Significance of signet-ring cells in patients with colorectal cancer. Dis Colon Rectum. 2008; 51(1): 50-55.
22. Wick MR, Vitsky JL, Ritter JH, Swanson PE, Mills SE. Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma. Am J Clin Pathol. 2005; 123(1): 56-65.
23. Thirunavukarasu P, Sathaiah M, Singla S, etal. Medullary carcinoma of the large intestine: a population based analysis. Int J Oncol. 2010; 37(4): 901-907.
24. Chetty R. Gastrointestinal cancers accompanied by a dense lymphoid component: an overview with special reference to gastric and colonic medullary and lymphoepithelioma-like carcinomas. J Clin Pathol. 2012; 65(12): 1062-1065.
25. Verdú M, Román R, Calvo M, etal. Clinicopathological and molecular characterization of colorectal micropapillary carcinoma. Mod Pathol. 2011; 24(5): 729-738.
26. Lino-Silva LS, Salcedo-Hernández RA, Caro-Sánchez CH. Colonic micropapillary carcinoma, a recently recognized subtype associated with histological adverse factors: clinicopathological analysis of 15 cases. Colorectal Dis. 2012; 14(9): e567-e572.
27. Lee HJ, Eom DW, Kang GH, etal. Colorectal micropapillary carcinomas are associated with poor prognosis and enriched in markers of stem cells. Mod Pathol. 2013; 26(8): 1123-1131.
28. Tuppurainen K, Mäkinen JM, Junttila O, etal. Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancer. J Pathol. 2005; 207(3): 285-294.
29. Mäkinen MJ. Colorectal serrated adenocarcinoma. Histopathology. 2007; 50(1): 131-150.
30. García-Solano J, Pérez-Guillermo M, Conesa-Zamora P, etal. Clinicopathologic study of 85 colorectal serrated adenocarcinomas: further insights into the full recognition of a new subset of colorectal carcinoma. Hum Pathol. 2010; 41(10): 1359-1368.
31. Shida Y, Fujimori T, Tanaka H, etal. Clinicopathological features of serrated adenocarcinoma defined by Mäkinen in Dukes' B colorectal carcinoma. Pathobiology. 2012; 79(4): 169-174.
32. Petrelli NJ, Valle AA, Weber TK, Rodriguez-Bigas M. Adenosquamous carcinoma of the colon and rectum. Dis Colon Rectum. 1996; 39(11): 1265-1268.
33. Masoomi H, Ziogas A, Lin BS, etal. Population-based evaluation of adenosquamous carcinoma of the colon and rectum. Dis Colon Rectum. 2012; 55(5): 509-514.
34. Betge J, Langner C. Vascular invasion, perineural invasion, and tumour budding: predictors of outcome in colorectal cancer. Acta Gastroenterol Belg. 2011; 74(4): 516-529.
35. van Wyk HC, Roxburgh CS, Horgan PG, etal. The detection and role of lymphatic and blood vessel invasion in predicting survival in patients with node negative operable primary colorectal cancer. Crit Rev Oncol Hematol. 2014; 90(1): 77-90.
36. Beaton C, Twine CP, Williams GL, etal. Systematic review and meta-analysis of histopathological factors influencing the risk of lymph node metastasis in early colorectal cancer. Colorectal Dis. 2013; 15(7): 788-797.
37. Bosch SL, Teerenstra S, de Wilt JH, etal. Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions. Endoscopy. 2013; 45(10): 827-834.
38. Jass JR, O'Brien J, Riddell RH, etal. Recommendations for the reporting of surgically resected specimens of colorectal carcinoma: Association of Directors of Anatomic and Surgical Pathology. Am J Clin Pathol. 2008; 129(1): 13-23.
39. Washington MK, Berlin J, Branton P, etal. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med. 2009; 133(10): 1539-1551.
40. Messenger DE, Driman DK, Kirsch R. Developments in the assessment of venous invasion in colorectal cancer: implications for future practice and patient outcome. Hum Pathol. 2012; 43(7): 965-973.
41. Betge J, Pollheimer MJ, Lindtner RA, etal. Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer. 2012; 118(3): 628-638.
42. Betge J, Schneider NI, Pollheimer MJ, etal. Is there a rationale to record lymphatic invasion in node-positive colorectal cancer? J Clin Pathol. 2012; 65(9): 847-850.
43. Harris EI, Lewin DN, Wang HL, etal. Lymphovascular invasion in colorectal cancer: an interobserver variability study. Am J Surg Pathol. 2008; 32(12): 1816-1821.
44. Batsakis JG. Nerves and neurotropic carcinomas. Ann Otoln Rhinol Laryngol. 1985; 94(4 Pt 1): 426-427.
45. Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: a review of the literature. Cancer. 2009; 115(15): 3379-3391.
46. Liebig C, Ayala G, Wilks J, etal. Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol. 2009; 27(31): 5131-5137.
47. Poeschl EM, Pollheimer MJ, Kornprat P, etal. Perineural invasion: correlation with aggressive phenotype and independent prognostic variable in both colon and rectum cancer. J Clin Oncol. 2010; 28(21): e358-e360; author reply e361-e362.
48. Peng J, Sheng W, Huang D, etal. Perineural invasion in pT3N0 rectal cancer: the incidence and its prognostic effect. Cancer. 2011; 117(7): 1415-1421.
49. Ueno H, Shirouzu K, Eishi Y, etal. Characterization of perineural invasion as a component of colorectal cancer staging. Am J Surg Pathol. 2013; 37(10): 1542-1549.
50. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum. 1993; 36(7): 627-635.
51. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002; 40(2): 127-132.
52. Ueno H, Mochizuki H, Hashiguchi Y, etal. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004; 127(2): 385-394.
53. Lugli A, Karamitopoulou E, Zlobec I. Tumour budding: a promising parameter in colorectal cancer. Br J Cancer. 2012; 106(11): 1713-1717.
54. Harbaum L, Pollheimer MJ, Kornprat P, Lindtner RA, Schlemmer A, Rehak P, Langner C. Keratin 7 expression in colorectal cancer-freak of nature or significant finding? Histopathology. 2011; 59(2): 225-234.
55. Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in stage II well-differentiated or moderately differentiated colon adenocarcinoma. Dis Colon Rectum. 2003; 46(10): 1400-1406.
56. Ueno H, Price AB, Wilkinson KH, Jass JR, Mochizuki H, Talbot IC. A new prognostic staging system for rectal cancer. Ann Surg. 2004; 240(5): 832-839.
57. Kanazawa H, Mitomi H, Nishiyama Y, etal. Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis. 2008; 10(1): 41-47.
58. Zlobec I, Terracciano L, Tornillo L, etal. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer. Gut. 2008; 57(10): 1413-1419.
59. Park KJ, Choi HJ, Roh MS, Kwon HC, Kim C. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum. 2005; 48(8): 1597-1602.
60. Choi HJ, Park KJ, Shin JS, Roh MS, Kwon HC, Lee HS. Tumor budding as a prognostic marker in stage-III rectal carcinoma. Int J Colorectal Dis. 2007; 22(8): 863-868.
61. Ohtsuki K, Koyama F, Tamura T. Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res. 2008; 28(3B): 1831-1836.
62. Nakamura T, Mitomi H, Kanazawa H, Ohkura Y, Watanabe M. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum. 2008; 51(5): 568-572.
63. Quirke P, Risio M, Lambert R, von Karsa L, Vieth M. Quality assurance in pathology in colorectal cancer screening and diagnosis-European recommendations. Virchows Arch. 2011; 458(1): 1-19.
64. Karamitopoulou E, Zlobec I, Kölzer V, etal. Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol. 2013; 26(2): 295-301.
65. Betge J, Kornprat P, Pollheimer MJ, etal. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Ann Surg Oncol. 2012; 19(12): 3706-3712.
66. Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol. 2012; 25(10): 1315-1325.
67. Horcic M, Koelzer VH, Karamitopoulou E, etal. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol. 2013; 44(5): 697-705.
68. Rogers AC, Gibbons D, Hanly AM, etal. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod Pathol. 2014; 27(1): 156-162.
69. Ueno H, Kajiwara Y, Shimazaki H, etal. New criteria for histologic grading of colorectal cancer. Am J Surg Pathol. 2012; 36(2): 193-201.
70. Ueno H, Hase K, Hashiguchi Y, etal. Novel risk factors for lymph node metastasis in early invasive colorectal cancer: a multi-institution pathology review. J Gastroenterol. Epub September 25, 2013.
71. Ueno H, Hase K, Hashiguchi Y, etal. Site-specific tumor grading system in colorectal cancer: multicenter pathologic review of the value of quantifying poorly differentiated clusters. Am J Surg Pathol. 2014; 38(2): 197-204.
72. Barresi V, Reggiani Bonetti L, Branca G, Di Gregorio C, Ponz de Leon M, Tuccari G. Colorectal carcinoma grading by quantifying poorly differentiated cell clusters is more reproducible and provides more robust prognostic information than conventional grading. Virchows Arch. 2012; 461(6): 621-628.
73. Barresi V, Bonetti LR, Ieni A, Branca G, Baron L, Tuccari G. Histologic grading based on counting poorly differentiated clusters in preoperative biopsy predicts nodal involvement and pTNM stage in colorectal cancer patients. Hum Pathol. 2014; 45(2): 268-275.
74. Swinson DE, Jones JL, Richardson D, Cox G, Edwards JG, O'Byrne KJ. Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Lung Cancer. 2002; 37(3): 235-240.
75. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002; 168(6): 2395-2400.
76. Langner C, Hutterer G, Chromecki T, Leibl S, Rehak P, Zigeuner R. Tumor necrosis as prognostic indicator in transitional cell carcinoma of the upper urinary tract. J Urol. 2006; 176(3): 910-913; discussion 913-914.
77. Zigeuner R, Shariat SF, Margulis V, etal. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol. 2010; 57(4): 575-581.
78. Pollheimer MJ, Kornprat P, Lindtner RA, etal. Tumor necrosis is a new promising prognostic factor in colorectal cancer. Hum Pathol. 2010; 41(12): 1749-1757.
79. Richards CH, Flegg KM, Roxburgh CS, etal. The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer. Br J Cancer. 2012; 106(12): 2010-2015.
80. Richards CH, Roxburgh CS, Anderson JH, etal. Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer. Br J Surg. 2012; 99(2): 287-294.
81. Komori K, Kanemitsu Y, Kimura K, etal. Tumor necrosis in patients with TNM stage IV colorectal cancer without residual disease (R0 status) is associated with a poor prognosis. Anticancer Res. 2013; 33(3): 1099-1105.
82. Guthrie GJ, Roxburgh CS, Richards CH, Horgan PG, McMillan DC. Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer. Br J Cancer. 2013; 109(1): 131-137.
83. Jass JR, Morson BC. Reporting colorectal cancer. J Clin Pathol. 1987; 40(9): 1016-1023.
84. Klintrup K, Mäkinen JM, Kauppila S, etal. Inflammation and prognosis in colorectal cancer. Eur J Cancer. 2005; 41(17): 2645-2654.
85. Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur J Cancer. 2009; 45(12): 2138-2145.
86. Powell AG, Ferguson J, Al-Mulla F, etal. The relationship between genetic profiling, clinicopathological factors and survival in patients undergoing surgery for node-negative colorectal cancer: 10-year follow-up. J Cancer Res Clin Oncol. 2013; 139(12): 2013-2020.
87. Ogino S, Nosho K, Irahara N, etal. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009; 15(20): 6412-6420.
88. Shia J, Ellis NA, Paty PB, etal. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol. 2003; 27(11): 1407-1417.
89. Greenson JK, Huang SC, Herron C, etal. Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol. 2009; 33(1): 126-133.
90. Nagtegaal ID, Marijnen CA, Kranenbarg EK, etal. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect-a histopathological and immunohistochemical study. BMC Cancer. 2001; 1: 7.
91. Deschoolmeester V, Baay M, Van Marck E, etal. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol. 2010; 11: 19.
92. Kim YW, Jan KM, Jung DH, Cho MY, Kim NK. Histological inflammatory cell infiltration is associated with the number of lymph nodes retrieved in colorectal cancer. Anticancer Res. 2013; 33(11): 5143-5150.
93. Richards CH, Roxburgh CS, Powell AG, Foulis AK, Horgan PG, McMillan DC. The clinical utility of the local inflammatory response in colorectal cancer. Eur J Cancer. 2014; 50(2): 309-319.
94. Galon J, Costes A, Sanchez-Cabo F, etal. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795): 1960-1964.
95. Galon J, Mlecnik B, Bindea G, etal. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014; 232(2): 199-209.
96. Lugli A, Karamitopoulou E, Panayiotides I, etal. CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. Br J Cancer. 2009; 101(8): 1382-1392.
97. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brünner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol. 1999; 189(4): 487-495.
98. Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, Aljama A. Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer. 2000; 88(7): 1544-1548.
99. Gulubova M, Ananiev J, Yovchev Y, Julianov A, Karashmalakov A, Vlaykova T. The density of macrophages in colorectal cancer is inversely correlated to TGF-β1 expression and patients' survival. J Mol Histol. 2013; 44(6): 679-692.
100. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res. 2007; 13(5): 1472-1479.
101. Chaput N, Svrcek M, Aupérin A, etal. Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer. Br J Cancer. 2013; 109(4): 1013-1022.